Elizabeth Bhatt
Director/Board Member at EFFECTOR THERAPEUTICS, INC.
Net worth: 5 195 $ as of 2024-03-30
Profile
Elizabeth P.
Bhatt is an Independent Director at eFFECTOR Therapeutics, Inc. and the Chief Operating Officer at Septerna, Inc. She previously served as an Independent Director at Locust Walk Acquisition Corp., Vice President-Corporate Development at Gilead Sciences, Inc., and Chief Operating & Business Officer at Achaogen, Inc. She also held the position of Chief Business & Strategy Officer at Applied Molecular Transport, Inc. Bhatt received her undergraduate degree from Pomona College, her graduate degree from the University of California San Diego, and her MBA from Kellogg School of Management.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2024-02-28 | 361 ( 0.01% ) | 5 195 $ | 2024-03-30 |
Elizabeth Bhatt active positions
Companies | Position | Start |
---|---|---|
EFFECTOR THERAPEUTICS, INC. | Director/Board Member | 2021-08-24 |
Septerna, Inc.
Septerna, Inc. Pharmaceuticals: MajorHealth Technology Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation. | Chief Operating Officer | 2022-07-27 |
Former positions of Elizabeth Bhatt
Companies | Position | End |
---|---|---|
ACHAOGEN | Chief Operating Officer | 2019-06-29 |
GILEAD SCIENCES, INC. | Corporate Officer/Principal | 2017-08-31 |
EFFECTOR THERAPEUTICS, INC. | Director/Board Member | - |
APPLIED MOLECULAR TRANSPORT INC. | Corporate Officer/Principal | - |
Training of Elizabeth Bhatt
Pomona College | Undergraduate Degree |
University of California San Diego | Graduate Degree |
Kellogg School of Management | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
APPLIED MOLECULAR TRANSPORT INC. | Health Technology |
EFFECTOR THERAPEUTICS, INC. | Health Technology |
Private companies | 3 |
---|---|
Achaogen, Inc.
Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Locust Walk Acquisition Corp.
Locust Walk Acquisition Corp. Financial ConglomeratesFinance Locust Walk Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on October 2, 2020 and is headquartered in Boston, MA. | Finance |
Septerna, Inc.
Septerna, Inc. Pharmaceuticals: MajorHealth Technology Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Elizabeth Bhatt